Featured
Health Topics
Any Category-
- Bacterial Infections and Mycoses 3
- Cardiovascular Diseases 5
- Chemically-Induced Disorders 1
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 17
- Digestive System Diseases 7
- Endocrine System Diseases 5
- Eye Diseases 2
- Female Urogenital Diseases and Pregnancy Complications 13
- Hemic and Lymphatic Diseases 25
- Immune System Diseases 11
- Male Urogenital Diseases 14
- Musculoskeletal Diseases 2
- Neoplasms 22
- Nervous System Diseases 13
- Nutritional and Metabolic Diseases 8
- Occupational Diseases 1
- Pathological Conditions, Signs and Symptoms 25
- Respiratory Tract Diseases 5
- Virus Diseases 3
- Wounds and Injuries 7
Search Clinical Trials
Terminated
Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT (External Link)
Patients will have received a haplo-identical stem cell transplant on our on-going study "CD45 (YTH-24 and YTH-54) and CD52 (Campath 1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell …
Baylor Role:
Lead Sponsor
Terminated
Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia (External Link)
Before patients receive any treatments, they will have the following: - Complete history and physical exam - Dental consultation - Bone marrow aspirate - Blood tests - Urinanalysis - Tests …
Baylor Role:
Lead Sponsor
Terminated
Intrathecal Gemcitabine to Treat Neoplastic Meningitis, IT Gemcitabine (External Link)
WHAT IS INVOLVED IN THE STUDY? Before participating in this study, there will be a screening process. Administration: Gemcitabine will be received directly into the cerebrospinal fluid (fluid that circulates …
Baylor Role:
Lead Sponsor
Terminated
Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML (External Link)
We expect that the patient's participation in this study will last approximately 18 months to 2 years. Before treatment begins, they will be evaluated to confirm they meet the requirements …
Baylor Role:
Lead Sponsor
Terminated
Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia (External Link)
If clinically feasible (no aplasia, no active malignancy), the recipients marrow will be harvested and cryopreserved as a back up for use if non-engraftment/rejection is followed by failure to undergo …
Baylor Role:
Lead Sponsor
Terminated
Oral Magnesium Pidolate, Hemoglobin SC Disease, MG Pidolate (External Link)
This is a placebo-controlled study which means that the effectiveness of the magnesium medication (the chemical form of which is known as Mg pidolate) will be compared to placebo. A …
Baylor Role:
Lead Sponsor
Terminated
Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies (External Link)
To do the stem cell transplant, we must first kill most of the cells in the bone marrow that make the sickle hemoglobin or abnormal blood cells of severe beta …
Baylor Role:
Lead Sponsor
Terminated
Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies (External Link)
To do the bone marrow transplant, we must first kill the cells in the bone marrow that make the abnormal red blood cells that are found in patients with severe …
Baylor Role:
Lead Sponsor
Terminated
Stem Cell Transplant for Hematologic Diseases (External Link)
Before treatment begins, stem cells will be collected from the donor's blood or bone marrow. The stem cells will be collected and frozen before we start to give the patient …
Baylor Role:
Lead Sponsor
Terminated
Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease (External Link)
We will take 60-70 ml (12 teaspoonfuls) of blood from the subject. We will first make a B cell line called a lymphoblastoid cell line or LCL by infecting the …
Baylor Role:
Lead Sponsor